Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Leigh Sowerby, Lawson Health Research Institute

ClinicalTrials.gov Identifier:

NCT01778465

First received: January 26, 2013

Last updated: March 1, 2015

Last verified: March 2015

History of Changes

Purpose

Aspirin-Exacerbated Respiratory Disease, or AERD, consists of aspirin sensitivity, asthma and nasal polyps. It is currently managed by chronic steroid use, multiple endoscopic sinus surgeries and/or aspirin desensitization. However, these treatments have potential adverse effects.

A theory has been postulated that decreasing the level of dietary salicylates may help in long-term control of disease. A current trial is in the works to evaluate the clinical outcomes of decreased salicylate, but measurements of biochemical markers of disease has not yet been done. The hypothesis is that decreased dietary salicylates will result in a decrease in urinary salicylates and inflammatory markers of disease, cys-leukotrienes, which are typically elevated in this disease.

Condition	Intervention
Chronic Rhinosinusitis Aspirin Exacerbated Respiratory Disease Asthma Aspirin Sensitivity	Behavioral: Low salicylate diet


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease

Resource links provided by NLM:

Drug Information available for: Aspirin

U.S. FDA Resources

Further study details as provided by Leigh Sowerby, Lawson Health Research Institute:

Primary Outcome Measures:

Urinary levels of Cys-Leukotrienes [ Time Frame: 14 days after commencement ]

Secondary Outcome Measures:

Urinary salicylate levels [ Time Frame: 14 days after enrollment ]


Enrollment:	14
Study Start Date:	May 2013
Study Completion Date:	May 2014
Primary Completion Date:	March 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Low salicylate diet Patients are to follow a low salicylate diet for one week.	Behavioral: Low salicylate diet Other Name: Dietary salicylate
No Intervention: Normal diet Patients are to continue with a normal diet for one week. There is then cross-over after one week for a further week into the intervention group.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

adult patients
Aspirin-exacerbated respiratory disease

Exclusion Criteria:

recent use of Prednisone or other systemic steroids (greater than 3 doses in past 3 months)
Endoscopic sinus surgery or polypectomy within the past 6 months
Other significant systemic disease, including renal failure, or immunocompromised state.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01778465

Locations


Canada, Ontario
St. Joseph's Health Care
London, Ontario, Canada, N5A 4V2

Sponsors and Collaborators

Lawson Health Research Institute

Investigators


Principal Investigator:	Leigh J Sowerby, MD	Lawson HRI

More Information


Responsible Party:	Leigh Sowerby, Assistant Professor, Otolaryngology, Lawson Health Research Institute
ClinicalTrials.gov Identifier:	NCT01778465 History of Changes
Other Study ID Numbers:	103330
Study First Received:	January 26, 2013
Last Updated:	March 1, 2015

Keywords provided by Leigh Sowerby, Lawson Health Research Institute:


Chronic Rhinosinusitis Aspirin exacerbated respiratory disease Asthma Aspirin sensitivity Salicylate

Additional relevant MeSH terms:


Respiration Disorders Respiratory Tract Diseases Immune System Diseases Hypersensitivity Aspirin Salicylates Salicylic Acid Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs	Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Anti-Infective Agents Antifungal Agents Keratolytic Agents Dermatologic Agents

ClinicalTrials.gov processed this record on June 28, 2017

To Top